H.C. Wainwright analyst Brandon Folkes reiterated a Buy rating and $8.00 price target on Traws Pharma Inc. (NASDAQ: TRAW).

The analyst commented: "TRAW reported 1Q26 results and secured the capital and development path needed to move tivoxavir marboxil (TXM), its lead influenza antiviral, into a human challenge study. The April PIPE financing provides $10.0M upfront and up to $60.0M in total potential gross proceeds through milestone-based and three-year warrants, which management expects to fund operations into 1Q27 and support completion of the planned TXM human influenza challenge trial. We view this as an important step in reducing the near-term cash overhang that has weighed on the stock, while keeping the core thesis intact: TRAW remains a highly asymmetric antiviral story where either TXM’s evolution into a once-monthly influenza prophylaxis/stockpile asset or ratutrelvir’s potential as a ritonavir-free COVID antiviral could drive meaningful value relative to the current market cap. Reiterate Buy and $8 PT."

For an analyst ratings summary and ratings history on Traws Pharma Inc. click here. For more ratings news on Traws Pharma Inc. click here.

Shares of Traws Pharma Inc. closed at $1.59 yesterday.